絞り込み

18370

広告

「"Pfreundschuh M "[Author]」の検索結果

489件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.

Progranulin autoantibodies in systemic sclerosis and autoimmune connective tissue disorders: A preliminary study.

High-resolution imaging of maltoporin LamB while quantifying the free-energy landscape and asymmetry of sugar-binding.

Incidence and inheritance of hyperphosphorylated paratarg-7 in patients with Waldenstrom's macroglobulinaemia in Sweden.

Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial.

Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.

Saposin C is a frequent target of paraproteins in Gaucher disease-associated MGUS/multiple myeloma.

Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease.

Age and Sex in Non-Hodgkin Lymphoma Therapy: It's Not All Created Equal, or Is It?

Hyper N-glycosylated SAMD14 and neurabin-I as driver CNS autoantigens of PCNSL.

Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity.

Safety and feasibility of electrical muscle stimulation in patients undergoing autologous and allogeneic stem cell transplantation or intensive chemotherapy.

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).

Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting.

ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients.

Mechanism of membrane pore formation by human gasdermin-D.

Progression-Free Survival at 24 Months (PFS24) and Subsequent Outcome For Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled On Randomized Clinical Trials.

Structural Properties of the Human Protease-Activated Receptor 1 Changing by a Strong Antagonist.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります